

The Medical Letter[®]

on Drugs and Therapeutics

Volume 66

August 19, 2024

ISSUE No.
1709

IN THIS ISSUE

In Brief: Expanded Indication for *Elevidys*p 135

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 66 (Issue 1709)

August 19, 2024

Take CME Exams

Update 6/17/25: The manufacturer of *Elevidys* has temporarily suspended its use in nonambulatory patients following a second fatal case of acute liver failure.

IN BRIEF

Expanded Indication for *Elevidys*

The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec-rokl (*Elevidys* – Sarepta) received accelerated approval from the FDA in 2023 for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.¹ It has now received full approval for use in ambulatory patients ≥ 4 years old and accelerated approval for use in nonambulatory patients with DMD.

MECHANISM OF ACTION — Delandistrogene moxeparvovec is a nonreplicating, recombinant AAV vector-based therapy that delivers a transgene encoding microdystrophin protein, a shortened protein that contains selected domains of the dystrophin protein expressed in normal muscle cells.

CLINICAL STUDIES — FDA approval of the expanded indications were based on the results of earlier trials in ambulatory patients 4-7 years old and an open-label trial in patients ≥ 3 years old with DMD. Patients who received a single IV infusion of delandistrogene moxeparvovec demonstrated increased expression of microdystrophin protein in skeletal muscle cells, a surrogate endpoint that is considered likely to predict clinical benefit in both ambulatory and nonambulatory patients. In one of the trials, changes were also observed in three secondary efficacy endpoints: time to rise from the floor, 10-meter walk/run, and time to ascend 4 steps. A double-blind, placebo-controlled trial (ENVISION) in nonambulatory patients with no age restrictions and older ambulatory patients (8-17 years old) is underway.²

ADVERSE EFFECTS — Acute serious liver injury has been reported with delandistrogene moxeparvovec. Immune-mediated myositis can occur, particularly in patients with deletions in exons 1-17 and/or exons 59-71 in the DMD gene. Nausea, vomiting, fever, thrombocytopenia, and myocarditis have also been reported.

DOSAGE AND COST — *Elevidys* is administered as a one-time IV infusion over 1-2 hours. It is contraindicated for use in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. The wholesale acquisition cost of one dose of *Elevidys* is \$3.2 million.³

CONCLUSION — The adeno-associated virus (AAV) vector-based gene therapy delandistrogene moxeparvovec (*Elevidys*) has received approval for treatment of Duchenne muscular dystrophy (DMD) in ambulatory and nonambulatory patients ≥ 4 years old who have a confirmed mutation in the DMD gene. Continued approval of *Elevidys* for use in nonambulatory patients is contingent on the results of an ongoing trial. The expanded approval now makes the very expensive gene therapy available to children and young men with DMD. ■

1. Delandistrogene moxeparvovec (*Elevidys*) for Duchenne muscular dystrophy. *Med Lett Drugs Ther* 2023; 65:159.
2. F Muntoni et al. ENVISION, a phase 3, randomized trial evaluating the safety and efficacy of delandistrogene moxeparvovec in Duchenne muscular dystrophy: study design. 28th International Annual Congress of the World Muscle Society (WMS); Charleston, USA; October 3-7, 2023.
3. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. July 5, 2024. Reprinted with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:





To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2024. ISSN 1523-2859

The
Medical
Letter